Eton Pharmaceuticals (ETON) Net Margin (2019 - 2025)

Eton Pharmaceuticals has disclosed Net Margin across 7 years of filings, most recently posting 6.97% for Q4 2025.

• Net Margin for Q4 2025 came in at 6.97%, up 1210.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 7.14% (up 266.0% YoY), and the FY2025 annual result was 5.75%, up 404.0% from the prior year.
• Net Margin came in at 6.97% for Q4 2025 at Eton Pharmaceuticals, up from 8.58% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 43.0% in Q1 2021 to a low of 786.32% in Q3 2021.
• The 5-year median for Net Margin is 9.38% (2024), against an average of 66.3%.
• Peak annual rise in Net Margin reached 2358427 bps in 2021, while the deepest fall reached 25621628 bps in 2021.
• Eton Pharmaceuticals' Net Margin stood at 17.05% in 2021, then slumped by 37 bps to 10.73% in 2022, then tumbled by 171 bps to 7.57% in 2023, then jumped by 32 bps to 5.13% in 2024, then surged by 236 bps to 6.97% in 2025.
• The last three Net Margin figures came in at 6.97% (Q4 2025), 8.58% (Q3 2025), and 13.66% (Q2 2025), per Business Quant data.